- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04314401
국립암연구소 "암문샷 바이오뱅크"
Cancer Moonshot Biobank 연구 프로토콜
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
연구 개요
상태
정황
- 악성 고형 신생물
- 흑색종
- 급성 골수성 백혈병
- 다발성 골수종
- 해부학적 III기 유방암 AJCC v8
- 해부학적 4기 유방암 AJCC v8
- 나팔관 암종
- 위암
- 폐 비소세포 암종
- 3기 폐암 AJCC v8
- IV기 폐암 AJCC v8
- 전이성 전립선암
- 난소 암종
- 식도암
- 침윤성 유방암
- IVB기 전립선암 AJCC v8
- 임상 IV기 위암 AJCC v8
- 임상 IV기 위식도 접합부 선암종 AJCC v8
- 삼중음성 유방암
- 4기 대장암 AJCC v8
- 원발성 복막 암종
- 임상 IV기 식도 선암종 AJCC v8
- 난소 고등급 장액성 선암종
- 3기 나팔관암 AJCC v8
- 3기 난소암 AJCC v8
- IV기 나팔관암 AJCC v8
- IV기 난소암 AJCC v8
- 호르몬 수용체 양성 유방암
- 폐 소세포 암종
상세 설명
PRIMARY OBJECTIVE:
I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.
SECONDARY OBJECTIVES:
I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.
II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.
III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.
IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.
V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.
VI. To provide residual biospecimens and associated data from the project to the cancer research community.
OUTLINE:
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
Alabama
-
Daphne, Alabama, 미국, 36526
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, 미국, 36532
- Thomas Hospital
-
Mobile, Alabama, 미국, 36607
- Mobile Infirmary Medical Center
-
Saraland, Alabama, 미국, 36571
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Kingman, Arizona, 미국, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Fort Smith, Arkansas, 미국, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Arroyo Grande, California, 미국, 93420
- PCR Oncology
-
Bakersfield, California, 미국, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Loma Linda, California, 미국, 92357
- Veterans Affairs Loma Linda Healthcare System
-
Salinas, California, 미국, 93901
- Salinas Valley Memorial
-
-
Colorado
-
Brighton, Colorado, 미국, 80601
- Intermountain Health Platte Valley Hospital
-
Denver, Colorado, 미국, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Golden, Colorado, 미국, 80401
- Lutheran Hospital - Cancer Centers of Colorado
-
Grand Junction, Colorado, 미국, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Lafayette, Colorado, 미국, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06102
- Hartford Hospital
-
-
Delaware
-
Dover, Delaware, 미국, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, 미국, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Boca Raton, Florida, 미국, 33486
- Boca Raton Regional Hospital
-
Deerfield Beach, Florida, 미국, 33064
- Broward Health North
-
Fort Lauderdale, Florida, 미국, 33316
- Broward Health Medical Center
-
Tampa, Florida, 미국, 33606
- Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, 미국, 30342
- Northside Hospital
-
Savannah, Georgia, 미국, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Illinois
-
Bloomington, Illinois, 미국, 61704
- Illinois CancerCare-Bloomington
-
Chicago, Illinois, 미국, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, 미국, 60625
- Swedish Covenant Hospital
-
Danville, Illinois, 미국, 61832
- Carle at The Riverfront
-
Decatur, Illinois, 미국, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, 미국, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, 미국, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, 미국, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, 미국, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, 미국, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, 미국, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, 미국, 62864
- SSM Health Good Samaritan
-
Pekin, Illinois, 미국, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, 미국, 61615
- Illinois CancerCare-Peoria
-
Urbana, Illinois, 미국, 61801
- Carle Cancer Center
-
Washington, Illinois, 미국, 61571
- Illinois CancerCare - Washington
-
-
Iowa
-
Ames, Iowa, 미국, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, 미국, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids, Iowa, 미국, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, 미국, 52402
- Physicians' Clinic of Iowa PC
-
Des Moines, Iowa, 미국, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, 미국, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, 미국, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Iowa City, Iowa, 미국, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70808
- Our Lady of the Lake Physician Group
-
New Orleans, Louisiana, 미국, 70118
- Children's Hospital New Orleans
-
New Orleans, Louisiana, 미국, 70112
- University Medical Center New Orleans
-
Shreveport, Louisiana, 미국, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, 미국, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, 미국, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, 미국, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brunswick, Maine, 미국, 04011
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Brunswick, Maine, 미국, 04011
- Mid Coast Hospital
-
Damariscotta, Maine, 미국, 04543
- MaineHealth LincolnHealth Hospital
-
Farmington, Maine, 미국, 04938
- MaineHealth Franklin Hospital
-
Lewiston, Maine, 미국, 04240
- Saint Mary's Regional Medical Center
-
Norway, Maine, 미국, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, 미국, 04102
- Maine Medical Partners Surgical Care
-
Portland, Maine, 미국, 04102
- MMP Surgical Care Casco Bay
-
Portland, Maine, 미국, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, 미국, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, 미국, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, 미국, 04074
- Maine Children's Cancer Program
-
Scarborough, Maine, 미국, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, 미국, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
South Portland, Maine, 미국, 04106
- MaineHealth Urology - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, 미국, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, 미국, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, 미국, 48118
- Chelsea Hospital
-
Grand Rapids, Michigan, 미국, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Iron Mountain, Michigan, 미국, 49801
- Dickinson County Healthcare System
-
Livonia, Michigan, 미국, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, 미국, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
-
Missouri
-
Ballwin, Missouri, 미국, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Joplin, Missouri, 미국, 64804
- Freeman Health System
-
Joplin, Missouri, 미국, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, 미국, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, 미국, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, 미국, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, 미국, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, 미국, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, 미국, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, 미국, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, 미국, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, 미국, 63128
- Mercy Hospital South
-
Washington, Missouri, 미국, 63090
- Mercy Hospital Washington
-
-
Montana
-
Billings, Montana, 미국, 59102
- Saint Vincent Frontier Cancer Center
-
Butte, Montana, 미국, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Grand Island, Nebraska, 미국, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
-
Nevada
-
Carson City, Nevada, 미국, 89703
- Carson Tahoe Regional Medical Center
-
Las Vegas, Nevada, 미국, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, 미국, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, 미국, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, 미국, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, 미국, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, 미국, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, 미국, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Hampshire
-
Nashua, New Hampshire, 미국, 03060
- Saint Joseph Hospital
-
-
New Jersey
-
Morristown, New Jersey, 미국, 07960
- Morristown Medical Center
-
Newton, New Jersey, 미국, 07860
- Newton Medical Center
-
Pompton, New Jersey, 미국, 07444
- Chilton Medical Center
-
Summit, New Jersey, 미국, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, 미국, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
The Bronx, New York, 미국, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, 미국, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, 미국, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, 미국, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, 미국, 27834
- East Carolina University
-
Greenville, North Carolina, 미국, 27834
- ECU Health Medical Center
-
Kernersville, North Carolina, 미국, 27284
- Novant Health Cancer Institute - Kernersville
-
Kinston, North Carolina, 미국, 28501
- ECU Health Oncology Kinston
-
Mount Airy, North Carolina, 미국, 27030
- Novant Health Cancer Institute - Mount Airy
-
Pinehurst, North Carolina, 미국, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Thomasville, North Carolina, 미국, 27360
- Novant Health Cancer Institute - Thomasville
-
Washington, North Carolina, 미국, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
Winston-Salem, North Carolina, 미국, 27103
- Novant Health Forsyth Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73120
- Mercy Hospital Oklahoma City
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02908
- Roger Williams Medical Center
-
-
South Carolina
-
Columbia, South Carolina, 미국, 29203
- Prisma Health Richland Hospital
-
Columbia, South Carolina, 미국, 29220
- Prisma Health Baptist Hospital
-
Gaffney, South Carolina, 미국, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, 미국, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, 미국, 29651
- Gibbs Cancer Center-Pelham
-
Spartanburg, South Carolina, 미국, 29303
- Spartanburg Medical Center
-
Union, South Carolina, 미국, 29379
- SMC Center for Hematology Oncology Union
-
-
Texas
-
San Antonio, Texas, 미국, 78229
- Audie L Murphy VA Hospital
-
-
Virginia
-
Lynchburg, Virginia, 미국, 24501
- Centra Alan B Pearson Regional Cancer Center
-
Richmond, Virginia, 미국, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, 미국, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton, Washington, 미국, 98055
- Valley Medical Center
-
Yakima, Washington, 미국, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Huntington, West Virginia, 미국, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, 미국, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Eau Claire, Wisconsin, 미국, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, 미국, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, 미국, 53215
- Aurora Saint Luke's Medical Center
-
Minocqua, Wisconsin, 미국, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, 미국, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, 미국, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, 미국, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, 미국, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
-
-
-
San Juan, 푸에르토 리코, 00917
- San Juan Community Oncology Group
-
San Juan, 푸에르토 리코, 00927
- Centro Comprensivo de Cancer de UPR
-
San Juan, 푸에르토 리코, 00936
- San Juan City Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients undergoing treatment for cancer types with commercially available therapies.
설명
Inclusion Criteria:
-
Is consistent with OR has been diagnosed with one of the following:
-
Colorectal cancer: stage IV
-
Non-small cell or small cell lung cancer: stage III/IV
-
Prostate cancer: metastatic prostate cancer
-
Gastric cancer, not otherwise specified (NOS): stage IV
-
Esophageal cancer, NOS: stage IV
-
Adenocarcinoma of gastroesophageal junction: stage IV
-
High grade serous ovarian cancer: stage III/IV
-
Invasive breast carcinoma: stage III/IV
-
Melanoma: stage III/IV
-
Acute myeloid leukemia
-
Multiple myeloma
-
For the purposes of this study,
- Re-staging is allowed
- Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
-
-
-
Patient should fit in one of the following four clinical scenarios (a-d)
- Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
- Scheduled to begin treatment with a new regimen of standard of care therapy OR
- Currently progressing on a regimen of standard of care therapy OR
- Currently being treated with a regimen standard of care therapy, without evidence of progression
-
Requirements for fresh tissue biospecimen collections at enrollment:
-
For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
-
For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
-
For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
-
For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
-
The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
- Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
-
-
-
Requirements for archival tissue:
-
For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
-
For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
-
Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:
- Contains the cancer type for which the participant is enrolled, and
- Was collected no more than 5 years prior to initiation of therapy, and
- Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
- Contains at least 10% tumor content. 70% tumor content is optimal, and
- No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
-
-
Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
- Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
- Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
-
Age 13 or older
-
Any sex
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
-
Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either
- Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
- African American with triple negative (ER-PR-HER2-)
-
NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)
Exclusion Criteria:
-
Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
- For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
-
Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
-
Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
-
Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
-
Factor X inhibitors are permitted
-
Use of anti-platelet drugs are permitted
- Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
-
-
NCI PDMR EXCLUSION CRITERIA: Patients with complete response
-
NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections
-
NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection
- Actively febrile patients with uncertain etiology of febrile episode
- All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
- No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
-
NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Observational (biospecimen collection, chart review)
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years. |
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo PET/CT
다른 이름들:
Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
다른 이름들:
Medical charts are reviewed and data is collected
다른 이름들:
Undergo paracentesis |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Procure, store and distribute longitudinal biospecimens and associated clinical data
기간: Up to 10 years
|
Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate. |
Up to 10 years
|
|
Percentage of enrolled patients by cancer type and treatment regimen overall
기간: Until completion of biospecimen collection, up to 3 years
|
Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of minority and underserved study participants accrued
기간: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of minority and underserved study participants accrued
기간: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Pan-cancer gene panel tumor next generation sequencing test
기간: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
기간: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling is attempted
기간: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling results are generated
기간: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
기간: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
기간: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Lyndsay N Harris, National Cancer Institute (NCI)
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 생식기 질환
- 내분비계 질환
- 혈관 질환
- 심혈관 질환
- 생식기 신생물, 남성
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 생식기 질환, 남성
- 전립선 질환
- 남성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 장 질환
- 면역계 질환
- 호흡기 질환
- 조직학적 유형에 따른 신생물
- 위장관 신생물
- 소화계 신생물
- 소화기계 질환
- 위장병
- 위장병
- 장 신생물
- 직장 질환
- 생식기 질환, 여성
- 폐 질환
- 혈액 질환
- 내분비샘 신생물
- 두경부 신생물
- 호흡기 신생물
- 흉부 신생물
- 결장 질환
- 식도 질환
- 난소 질환
- 부속기 질환
- 생식기 신생물, 여성
- 생식선 장애
- 피부병
- 유방 질환
- 림프 증식 장애
- 면역증식성 장애
- 신경외배엽 종양
- 신생물, 생식 세포 및 배아
- 신생물, 신경 조직
- 백혈병, 골수성
- 기관지 암종
- 기관지 신생물
- 신경내분비종양
- 신생물, 형질세포
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 출혈성 장애
- 백혈병
- 모반과 흑색종
- 피부 신생물
- 나팔관 질환
- 유방 신생물
- 피부 및 결합 조직 질환
- 헴 및 림프병
- 전립선 신생물
- 위 신생물
- 폐 신생물
- 대장 신생물
- 백혈병, 골수성, 급성
- 식도 신생물
- 난소 신생물
- 암종, 비소세포폐
- 다발성 골수종
- 소세포폐암
- 흑색종
- 삼중 음성 유방 신생물
- 나팔관 신생물
- 조사 기술
- 치료학
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 구멍
- 수술 절차, 수술
- 화학 기술, 분석
- 스펙트럼 분석
- 배수
- 시편 처리
- 자기 공명 분광법
- Paracentesises
기타 연구 ID 번호
- NCI-2020-00750
- NCI-2020-00750 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- 10323 (기타 식별자: CTEP)
- 10323 (기타 식별자: Division of Cancer Treatment and Diagnosis)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .